Mesothelioma Nutrition and Supportive Care

Mesothelioma Nutrition
Malnutrition at Diagnosis	38% (Help-Meso study)
Pre-Sarcopenic at Baseline	54%
Appetite Loss Reported	87% of patients
Low PNI Death Risk	HR 2.29 (PNI <44.6)
Hypoalbuminemia 1-Year OS	44.1% vs 72.0%
Recommended Energy Intake	25-30 kcal/kg/day
Recommended Protein	1.0-1.5 g/kg/day
B12/Folate OS Benefit	+5 months with pemetrexed
Free Case Review

Executive Summary

Mesothelioma patients face a uniquely severe nutritional burden that directly affects survival outcomes. The Help-Meso study found that 38% of malignant pleural mesothelioma (MPM) patients meet formal malnutrition criteria and 54% are pre-sarcopenic at diagnosis, rates substantially exceeding most thoracic cancers. Malnutrition in MPM is independently associated with a relative risk of death of 1.73 (95% CI 1.23-2.41), and the prognostic nutritional index (PNI) is a validated survival predictor with patients scoring below 44.6 facing a hazard ratio for death of 2.29 (95% CI 1.415-3.706; p=0.001) compared to those with higher PNI. Serum albumin below 35 g/L is associated with 1-year survival of 44.1% versus 72.0% in patients with normal albumin levels, and each 1 g/L albumin increment reduces the hazard of death by 9.8%.

Despite this severe nutritional burden, no dedicated mesothelioma nutrition randomized controlled trials exist as of March 2026. All clinical nutrition guidance is extrapolated from broader oncology literature, principally the ESPEN Practical Guideline on Clinical Nutrition in Cancer (2021), which recommends 25-30 kcal/kg/day total energy and 1.0-1.5 g protein/kg/day for all cancer patients. The most important nutrition-related finding in mesothelioma treatment is that mandatory folic acid (350-1,000 mcg/day) and vitamin B12 (1,000 mcg intramuscularly every 9 weeks) supplementation with pemetrexed chemotherapy produces a 5-month survival benefit (13.3 vs 8.1 months median overall survival) while significantly reducing severe toxicity.

Emerging evidence links dietary patterns to immunotherapy outcomes, which has direct relevance given that nivolumab plus ipilimumab is now first-line standard therapy for MPM. The PRIMM study found that higher Mediterranean diet adherence was significantly associated with immune checkpoint inhibitor response (probability of ORR 0.77; p=0.02), and a 2025 systematic review reported that high dietary fiber intake was associated with a pooled OR of 5.79 for improved immunotherapy response. These findings underscore that nutrition management in mesothelioma extends far beyond caloric adequacy to encompass treatment efficacy and survival outcomes. Mesothelioma patients and families navigating treatment decisions may also benefit from consulting experienced mesothelioma attorneys who can help coordinate legal compensation alongside medical care.

At-a-Glance

Mesothelioma nutrition and supportive care at a glance:

• 38% of MPM patients are malnourished at diagnosis -- the Help-Meso prospective study found malnutrition and 54% pre-sarcopenia rates at baseline using GLIM criteria
• Malnutrition death risk HR 1.73 -- independently linked to a 73% increased risk of death in MPM cohorts
• PNI below 44.6 doubles death risk -- hazard ratio 2.29 (p=0.001); median survival 11 months vs 18 months in PNI-high patients
• Hypoalbuminemia cuts 1-year survival from 72% to 44% -- each 1 g/L albumin increase reduces death hazard by 9.8%
• Folic acid and B12 add 5 months survival -- mandatory supplementation with pemetrexed reduces severe toxicity and extends median OS from 8.1 to 13.3 months
• ESPEN recommends 25-30 kcal/kg/day and 1.0-1.5 g protein/kg/day -- the standard energy and protein targets for all cancer patients during treatment
• Mediterranean diet improves immunotherapy response -- probability of overall response rate 0.77 (p=0.02) with higher adherence in ICI-treated patients
• High fiber intake linked to 5.79x better ICI response -- systematic review of prospective cohorts shows dietary fiber strongly predicts immunotherapy benefit
• 29.3% of CRS/HIPEC patients require parenteral nutrition -- postoperative ileus is the most common indication (63.1% of cases)
• 75% of mesothelioma caregivers report personal health impacts -- nutritional distress and feeding conflicts contribute to caregiver burden including possible PTSD in up to 33%

Key Facts

Measure	Finding (Source)
Malnutrition Rate at Diagnosis	38% meet malnutrition criteria -- Help-Meso study, Aujayeb et al., 2022
Pre-Sarcopenia at Baseline	54% of MPM patients -- Help-Meso study, GLIM criteria
Appetite Loss Prevalence	87% of MPM patients; fatigue 94%, dyspnea 89% -- Lippi et al., 2024, PMID: 39195261
PNI Prognostic Cutoff	PNI <44.6: HR 2.29 for death (p=0.001); 18 vs 11 months median OS -- Yao et al., 2013, PMID: 24149776
Albumin and 1-Year Survival	44.1% vs 72.0% (albumin <=35 vs >35 g/L) -- Yao et al., 2014, PMID: 25051913
mGPS Prognostic Value	HR 2.6 (p<0.001) in multivariate analysis -- Pinato et al., 2012, PMID: 22307011
ESPEN Energy Target	25-30 kcal/kg/day total energy expenditure -- ESPEN 2021 Guideline
ESPEN Protein Target	1.0-1.5 g/kg/day; up to 2.0 g/kg/day perioperatively -- ESPEN 2021 Guideline
B12/Folate Survival Benefit	+5 months median OS with pemetrexed supplementation (13.3 vs 8.1 months) -- Manegold et al., 2003, PMID: 12697881
Mediterranean Diet and ICI	ORR probability 0.77 (p=0.02) with higher adherence -- Spencer et al., JAMA Oncology 2023
Fiber and ICI Response	OR 5.79 for improved response (prospective cohorts) -- Somodi et al., J Transl Med 2025
Post-HIPEC PN Requirement	29.3% of 222 CRS patients; ileus main indication (63.1%) -- PMID: 37739696

How Does Malnutrition Affect Mesothelioma Prognosis?

Malnutrition in mesothelioma is not merely a quality-of-life concern but an independent predictor of death. The Help-Meso study, a prospective cohort specifically enrolling malignant pleural mesothelioma patients, found that 38% met criteria for malnutrition and 54% were pre-sarcopenic at the time of diagnosis using GLIM criteria and handgrip dynamometry. These rates substantially exceed baseline malnutrition rates seen in early-stage lung adenocarcinoma, reflecting the inflammatory biology of asbestos-induced pleural disease and the typically advanced stage at MPM diagnosis.

Multiple compounding barriers to adequate nutrition affect mesothelioma patients. Appetite loss is reported by 87% of MPM patients, fatigue by 94%, dyspnea by 89%, and pain by 85%. Tumor-induced cytokine release (IL-6, TNF-alpha, IL-1beta) drives anorexia, accelerated muscle catabolism, and lipolysis. Pleural effusions in MPM cause early satiety and dyspnea during eating, while malignant ascites in peritoneal mesothelioma causes abdominal distension and nausea. Treatment toxicity from pemetrexed, cisplatin, and immunotherapy further impairs nutritional status.

Prognostic Nutritional Index (PNI)

The PNI is calculated as: (10 x serum albumin in g/dL) + (0.005 x total lymphocyte count per mm3). A landmark study of 121 histologically confirmed MPM patients found that PNI below 44.6 carried a hazard ratio for death of 2.290 (95% CI 1.415-3.706; p=0.001). Median overall survival was 18 months for PNI-high patients versus 11 months for PNI-low patients (p=0.003), with 1-year survival rates of 72.3% versus 45.5% and 2-year survival rates of 38.7% versus 18.4%.

A second retrospective study of 132 MPM patients validated PNI as an independent prognostic factor, finding that PNI below 40 combined with age 65 or older and non-epithelioid histology produced median overall survival of just 9 months versus 21 months in the good prognostic group, with 1-year survival rates of 29.7% versus 77.9%. A 2024 Chinese validation study further confirmed PNI and pleural thickness as joint prognostic tools in MPM evaluation.

Serum Albumin

In a retrospective study of 97 MPM patients receiving platinum-based chemotherapy, 35.1% had hypoalbuminemia (albumin at or below 35 g/L) at baseline. One-year overall survival was 44.1% in the hypoalbuminemic group versus 72.0% in patients with normal albumin (p<0.001). Multivariate analysis demonstrated that each 1 g/L increment in albumin reduced the hazard of death by 9.8% (HR 0.902, 95% CI 0.851-0.956; p=0.031). These findings establish serum albumin as a practical, widely available prognostic marker that should be routinely monitored in mesothelioma patients. Understanding prognosis factors can help patients and families make informed treatment and legal decisions.

Modified Glasgow Prognostic Score (mGPS)

The mGPS captures systemic inflammatory burden through two serum markers: C-reactive protein (CRP) and albumin. A score of 0 (CRP at or below 10 mg/L) indicates best prognosis, score 1 (CRP above 10 mg/L with albumin at or above 35 g/L) indicates intermediate prognosis, and score 2 (CRP above 10 mg/L and albumin below 35 g/L) indicates worst prognosis.

In a validation study of inflammation-based indices in MPM, multivariate analysis confirmed mGPS (HR 2.6; p<0.001) and neutrophil-to-lymphocyte ratio (HR 2.0; p=0.008) as independent predictors of overall survival, outperforming the European EORTC Prognostic Score. A larger multicenter analysis identified the CRP/albumin ratio (CAR) as a strong independent prognostic factor, with epithelioid histology patients having low CAR achieving overall survival of 32.0 months versus 11.0 months (p<0.001). The Mesothelioma Systemic Inflammation Score (MSIS), a 2025 novel composite score validated in a large cohort, demonstrated independent prognostic value for overall survival and predictive value for benefit from multimodality treatment.

What Are the Evidence-Based Nutrition Guidelines for Mesothelioma?

ESPEN Practical Guideline on Clinical Nutrition in Cancer (2021)

The ESPEN Practical Guideline is the most comprehensive applicable guideline for mesothelioma patients, as no mesothelioma-specific nutrition guideline exists. Key recommendations include:

Recommendation	Strength	Detail
Screen all cancer patients at diagnosis	Strong	NRS-2002, PG-SGA, or MUST validated tools
Total energy: 25-30 kcal/kg/day	Strong	Use indirect calorimetry where available
Protein: 1.0-1.5 g/kg/day (target 1.5)	Strong	Higher end for weight-losing, sarcopenic patients
Vitamins/minerals at RDA levels	Strong	No high-dose supplementation unless deficiency documented
Omega-3/fish oil for weight-losing patients	Weak	1-4 g/day EPA+DHA on chemotherapy
ERAS protocols for surgical patients	Strong	Mandates early enteral nutrition post-operatively
No routine ANH in actively dying patients	Strong (consensus)	Ethical comfort-focused standard

For mesothelioma patients specifically, protein targets should be at the higher end (1.2-1.5 g/kg/day) given the 54% baseline sarcopenia rate, active catabolism, and likelihood of major surgery or systemic treatment.

Pemetrexed Mandatory Vitamin Supplementation

Folic acid and vitamin B12 supplementation is a mandatory pharmaceutical protocol requirement for all patients receiving pemetrexed, the cornerstone of mesothelioma chemotherapy. The pivotal Phase III randomized controlled trial enrolled 456 MPM patients. After protocol amendment adding folic acid and B12, grade 3/4 toxicities were significantly reduced and median overall survival was 12.1 months versus 9.3 months (HR 0.77; p=0.020). A Phase II single-agent pemetrexed trial confirmed that supplemented patients had 5-month greater median OS (13.3 vs 8.1 months) with less toxicity.

The standardized protocol requires folic acid 350-1,000 mcg/day orally, initiated 7 days before first pemetrexed dose and continued throughout treatment and for 21 days after the final dose, plus vitamin B12 1,000 mcg intramuscularly every 9 weeks. Same-day B12 administration has been retrospectively validated in 281 patients with no significant difference in hematologic outcomes, enabling scheduling flexibility. Pemetrexed is a folate analog antifolate; without folic acid and B12, homocysteine accumulates and the drug inhibits normal-tissue folate metabolism disproportionately relative to tumor kill. Supplementation selectively restores normal-tissue folate metabolism without meaningfully protecting cancer cells. Patients seeking more information about mesothelioma treatment options including chemotherapy protocols can access comprehensive resources online.

What Should Mesothelioma Patients Eat During Chemotherapy?

Anti-Inflammatory Dietary Patterns

The Mediterranean diet is the best-studied anti-inflammatory dietary pattern in oncology with direct relevance to mesothelioma patients receiving immunotherapy. The PRIMM study of 91 advanced melanoma patients on immune checkpoint inhibitors found that higher adherence to Mediterranean dietary principles was significantly associated with probability of response (probability of ORR 0.77; p=0.02), driven by whole grains, fish, nuts, fruit, vegetables, and legumes.

Since nivolumab plus ipilimumab is now first-line standard therapy for MPM, this dietary-immunotherapy relationship has direct clinical relevance. A 2025 systematic review found that high versus low dietary fiber intake was associated with a pooled OR of 5.79 for improved ICI response in prospective cohort studies. A 2025 clinical intervention study of 132 cancer survivors showed significant post-intervention reduction in IL-1beta, IL-6, IL-8, and TNF-alpha with Mediterranean diet adherence, confirming anti-inflammatory mechanisms.

Managing Chemotherapy Side Effects Through Diet

Side Effect	Dietary Strategy	Evidence Basis
Nausea/vomiting	Ginger products; small dry starchy foods before meals; cold/room temperature foods	General oncology RCTs; ginger RCTs in chemotherapy patients
Mucositis	Soft, cool, non-acidic foods; saline/baking soda rinses 4-6 times daily; avoid alcohol/tobacco	ESPEN guidelines; standard oncology practice
Dysgeusia (metallic taste)	Plastic/bamboo utensils; cold foods; marinate meats in sweet/acid sauces	Clinical oncology nutrition practice
Early satiety	Liquid calories (smoothies, protein shakes, soups); 5-6 small meals; avoid large volume drinks with meals	ESPEN practical guidance; peritoneal-specific guidance
Appetite loss	Eat by schedule regardless of hunger; high-calorie additions (olive oil, nut butters, avocado)	ESPEN 2021 ONS guidance
Fatigue affecting cooking	Pre-prepared nutrient-dense meals; assistance from caregivers; ready-to-drink oral nutritional supplements	Help-Meso study patient data

Hydration During Cisplatin Treatment

Adequate hydration is a renal cytoprotection strategy essential during cisplatin-based chemotherapy. Cisplatin-induced nephrotoxicity rates of 25-33% have been reported in cohort studies. Standard clinical protocol requires prehydration with 1-2 liters of intravenous normal saline over 1-2 hours before cisplatin, with post-hydration maintained for 2-6 hours. On non-infusion days, oral hydration targets are 8-10 glasses daily (approximately 2-2.5 liters).

Cisplatin causes dose-dependent hypomagnesemia, hypokalemia, and hyponatremia, with metabolic and nutritional disorders reported in 33.3% of patients in immunotherapy combination trials. Electrolyte monitoring and replacement is essential throughout cisplatin-containing regimens.

Oral Nutritional Supplements

High-protein oral nutritional supplements (ONS) providing 1.5-2 kcal/mL and at least 20 g protein per serving are indicated when oral intake remains inadequate despite nutritional counseling, when weight loss continues despite dietary modification, or when treatment side effects prevent adequate solid food intake. ESPEN 2021 recommends ONS as the escalation step before enteral tube feeding: first counseling, then ONS, then enteral nutrition, then parenteral nutrition.

Which Supplements Are Safe During Mesothelioma Treatment?

Mandatory Supplements: Folic Acid and Vitamin B12

As detailed above, folic acid (350-1,000 mcg/day) and vitamin B12 (1,000 mcg IM every 9 weeks) are mandatory pharmaceutical requirements for all patients receiving pemetrexed, proven to extend survival by 5 months and significantly reduce grade 3/4 toxicities.

Omega-3 Fatty Acids

EPA and DHA modulate pro-inflammatory cytokines (IL-6, TNF-alpha) that drive cachexia. A prospective randomized controlled trial in gastrointestinal cancer patients found that fish oil prevented increases in serum CRP and significantly increased skeletal muscle mass and lean body mass compared to controls, with specific benefit in patients with mGPS scores of 1 or 2. ESPEN 2021 provides a weak recommendation for omega-3 fatty acids (1-4 g/day EPA+DHA) for advanced cancer patients on chemotherapy at risk of weight loss. No mesothelioma-specific omega-3 evidence exists; all data is extrapolated from pancreatic, gastrointestinal, and general advanced cancer populations. Omega-3s may reduce platelet aggregation and should be discontinued 5-7 days before surgery.

Glutamine for Mucositis

Pemetrexed-based chemotherapy can cause oral and gastrointestinal mucositis. A meta-analysis of 15 RCTs with 988 participants found that glutamine significantly reduced mucositis severity (SMD -0.73), reduced incidence of severe (Grade 3-4) mucositis (RR 0.41), reduced opioid analgesic use (RR 0.84), feeding tube use (RR 0.46), hospitalization (RR 0.39), and treatment interruption (RR 0.49). A controlled trial confirmed glutamine significantly decreased mean maximal mucositis grade (2.9 vs 3.3; p=0.005).

Vitamin D

Vitamin D deficiency is common in cancer patients. The only mesothelioma-specific pre-clinical data comes from a mouse model study that found vitamin D supplementation did not reduce mesothelioma incidence or severity in asbestos-exposed mice. The large VITAL trial (25,871 participants, 2000 IU/day vitamin D) found no significant reduction in cancer incidence, though cancer mortality was reduced in secondary analyses after year 2. The clinical recommendation is to screen for deficiency and correct to normal levels (above 20 ng/mL); ESPEN does not support supplementation beyond documented deficiency correction.

Supplements to Avoid During Treatment

Supplement	Interaction Risk	Recommendation
High-dose vitamin C (>1 g/day)	May reduce cisplatin efficacy via ROS neutralization	Avoid during active treatment
High-dose vitamin E	Same ROS neutralization mechanism as vitamin C	Avoid during active treatment
Beta-carotene	Increased lung cancer incidence in smokers (ATBC, CARET trials)	Avoid especially in smoking-history patients
St. John's Wort	CYP450 inducer; alters cisplatin and pemetrexed metabolism	Avoid -- known drug interaction
High-dose garlic supplements	CYP450 modulation; platelet inhibition	Avoid during treatment
Ginseng (Panax)	CYP450 interactions; may interfere with chemotherapy	Avoid during active treatment

A multivitamin providing RDA-level nutrients is generally considered safe during treatment. Mega-dose supplementation of any kind requires oncologist review before each chemotherapy cycle.

What Are the Nutritional Needs for Peritoneal Mesothelioma Patients?

Diffuse malignant peritoneal mesothelioma (DMPM) represents approximately 15% of all mesotheliomas and creates nutritional challenges qualitatively different from pleural disease.

Disease-Specific Challenges

Malignant ascites causes severe abdominal distension, early satiety, nausea, and dyspnea from diaphragmatic compression. Each liter of ascitic fluid contains 3-5 g protein; large-volume paracentesis removes liters, rapidly depleting protein reserves. Management includes albumin infusion (6-8 g/L drained) post-large-volume paracentesis, high-protein oral diet, and sodium restriction below 2 g/day if cirrhotic physiology is present.

Bowel involvement from peritoneal disease studding can cause small bowel adhesions, malignant bowel obstruction, and malabsorption. When obstruction occurs, oral nutrition becomes impossible or severely limited, and parenteral nutrition becomes the primary route for patients awaiting surgery or palliative intervention.

CRS/HIPEC Nutritional Management

Cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) is the curative-intent treatment of choice for DMPM, achieving median overall survival of approximately 50 months at specialized centers. CRS/HIPEC carries a 30-46% complication rate and imposes unique nutritional demands.

A 2024 retrospective analysis of 140 CRS/HIPEC patients confirmed that preoperative nutritional status was significantly associated with postoperative outcomes: patients requiring parenteral nutrition had significantly longer post-operative, hospital, and ICU length of stay (p=0.001). Malnutrition before HIPEC independently predicted requirement for parenteral nutrition and worse outcomes.

Phase	Nutritional Challenge	Recommended Strategy
Pre-HIPEC (4-8 weeks)	Malnutrition, ascites protein losses	1.5-2.0 g protein/kg/day; albumin correction; omega-3; carbohydrate loading 24h pre-op
Early post-op (Days 0-3)	Post-HIPEC ileus, stress response	Early enteral nutrition preferred if feasible
Later post-op (Days 3-14)	Partial ileus, pain, poor appetite	ONS; high-protein soft foods; advance diet as tolerated
Post-discharge chemotherapy	Systemic chemotherapy side effects	Standard pemetrexed protocol with mandatory folic acid and B12

A UK national retrospective study found that most CRS/HIPEC patients required parenteral nutrition for more than 7 days, with poor pre-operative nutritional status and incomplete cytoreduction as independent predictors of prolonged PN requirement and a median PN duration of 9 days (range 1-87 days). Among 222 CRS patients at Peter MacCallum Cancer Centre, 29.3% required postoperative PN, with postoperative ileus as the most frequent indication (63.1% of PN cases). Enteral nutrition was identified as an independent protective factor for postoperative hospital stay and complications (p=0.001) in CRS/HIPEC patients, with shorter length of stay and lower complication rates than parenteral nutrition alone.

Peritoneal mesothelioma patients undergoing CRS/HIPEC should receive pre-operative nutritional assessment and optimization as part of their multidisciplinary care plan.

How Should Nutrition Be Managed in Palliative Mesothelioma Care?

MPM median survival is 12-18 months for pleural disease, creating an obligation to calibrate nutritional intensity to the goals of care across three distinct phases.

Active Treatment Phase

During chemotherapy or immunotherapy, the goal is weight maintenance, muscle preservation, and treatment completion. Targets include 25-30 kcal/kg/day energy, 1.2-1.5 g protein/kg/day, and dietitian involvement from diagnosis.

Palliative Phase

When disease progresses beyond active treatment options, nutritional goals shift to quality of life, comfort, and symptom management. Dietary targets become relaxed and patient preference-guided, with counseling prioritized over prescriptive caloric targets.

Terminal Phase

ESPEN 2021 guidance states that during the dying phase when death is expected within days, nutritional and metabolic support is usually not indicated. Terminal cancer anorexia is a cytokine-driven state that cannot be reversed by increasing caloric input alone. Artificial nutrition and hydration (ANH) at end of life does not significantly improve survival or quality of life in terminal cancer patients.

Short-term parenteral hydration may be indicated when delirium is present and dehydration is a plausible contributing cause. ESPEN supports this as a time-limited therapeutic trial, not routine practice.

Family and Caregiver Guidance

Families often experience profound distress when their loved one refuses food. A 2024 mesothelioma-specific systematic review confirmed that 75% of mesothelioma caregivers report personal health impacts and up to 33% develop possible PTSD. Nutritional distress and conflict over feeding are embedded in this broader caregiver burden.

Key messages for families include: inadequate calorie intake in terminal cancer reflects the dying process and not a failure of caregiving; pressure to eat increases patient anxiety, nausea, and discomfort without providing survival benefit; small amounts of preferred foods provide sensory pleasure and emotional connection without imposing clinical goals; and artificial nutrition should not be equated with giving up. Mesothelioma support resources are available for patients and families navigating these difficult decisions.

What Clinical Studies Support Nutritional Interventions in Mesothelioma?

Study	Year / N	Key Finding
Help-Meso (Aujayeb et al.)	2022 / Prospective	38% malnutrition, 54% pre-sarcopenia at MPM diagnosis
PNI in MPM (Yao et al.)	2013 / n=121	PNI <44.6: HR 2.29 for death (p=0.001); 18 vs 11 months OS
Albumin in MPM (Yao et al.)	2014 / n=97	Hypoalbuminemia HR 1.778; 44.1% vs 72.0% 1-year OS
mGPS/NLR in MPM (Pinato et al.)	2012 / Retrospective	mGPS HR 2.6 (p<0.001); NLR HR 2.0 (p=0.008)
PNI in 132 MPM (Cakir et al.)	2022 / n=132	PNI <40: independent poor prognostic factor; 9 vs 21 months OS
CAR in MPM (Multicenter)	2025 / Multicenter	Epithelioid with low CAR: OS 32.0 vs 11.0 months (p<0.001)
MSIS Score Validation	2025 / Large cohort	Independent prognostic and predictive value for multimodality benefit
Pemetrexed Phase III (Vogelzang)	2003 / n=456	B12/folate supplementation: 12.1 vs 9.3 months OS (HR 0.77; p=0.020)
Pemetrexed Phase II (Manegold)	2003 / Phase II	Supplemented: 13.3 vs 8.1 months OS (+5 months)
Fish oil and chemotherapy (Fujimoto)	2017 / RCT	Prevented CRP rise; increased muscle mass in mGPS 1/2 patients
Glutamine meta-analysis (Wang)	2021 / 15 RCTs, 988	Reduced severe mucositis (RR 0.41), hospitalization (RR 0.39)
Post-HIPEC PN (222 CRS patients)	2023 / n=222	29.3% required post-op PN; ileus main indication (63.1%)

No registered Phase II or III RCTs exist that study nutrition interventions specifically and exclusively in mesothelioma patients as of March 2026. The Help-Meso study is the most mesothelioma-specific nutritional study. The MMP-LUNG trial is an ongoing RCT of a multinutrient supplement (whey protein, leucine, vitamin D, fish oil) plus exercise in lung cancer that is extrapolatable to mesothelioma.

Frequently Asked Questions

What is the best diet for mesothelioma patients?

There is no single best diet for mesothelioma patients, but the ESPEN 2021 guidelines recommend 25-30 kcal/kg/day total energy and 1.0-1.5 g protein/kg/day for all cancer patients during treatment. A Mediterranean-style dietary pattern emphasizing whole grains, fish, nuts, fruits, vegetables, and legumes has shown significant association with improved immunotherapy response and anti-inflammatory effects. Patients should work with an oncology dietitian to create an individualized nutrition plan that accounts for their specific treatment regimen, symptoms, and nutritional status.

Are folic acid and vitamin B12 required during mesothelioma chemotherapy?

Yes. Folic acid (350-1,000 mcg/day orally) and vitamin B12 (1,000 mcg IM every 9 weeks) are mandatory pharmaceutical requirements for all patients receiving pemetrexed, the cornerstone of mesothelioma chemotherapy. These supplements are not optional -- they are proven to reduce severe toxicity and provide a 5-month survival benefit. Folic acid must be started 7 days before the first pemetrexed dose and continued throughout treatment and for 21 days after the final dose.

Should mesothelioma patients take antioxidant supplements?

High-dose antioxidant supplements (vitamins C, E, beta-carotene, selenium) should generally be avoided during active chemotherapy because cisplatin and pemetrexed generate reactive oxygen species as part of their cancer-killing mechanism. High-dose antioxidants may neutralize these effects, potentially reducing treatment efficacy. A standard multivitamin at RDA levels is generally considered safe. Any supplementation beyond basic levels requires oncologist approval before each chemotherapy cycle.

How does malnutrition affect mesothelioma survival?

Malnutrition is an independent predictor of death in mesothelioma. Patients with low prognostic nutritional index (PNI <44.6) face more than double the risk of death (HR 2.29; p=0.001), with median survival of 11 months versus 18 months in well-nourished patients. Hypoalbuminemia (albumin at or below 35 g/L) is associated with 1-year survival of just 44.1% versus 72.0% in patients with normal albumin. Nutritional screening at diagnosis and throughout treatment is essential.

What should peritoneal mesothelioma patients eat before HIPEC surgery?

Peritoneal mesothelioma patients preparing for CRS/HIPEC should undergo 4-8 weeks of nutritional prehabilitation with aggressive protein repletion (1.5-2.0 g/kg/day), albumin correction, omega-3 supplementation, and carbohydrate loading 24 hours before surgery. Pre-operative malnutrition independently predicts requirement for parenteral nutrition and worse surgical outcomes. Patients should work closely with a surgical team and dietitian at a specialized mesothelioma treatment center.

When should artificial nutrition be stopped in terminal mesothelioma?

ESPEN 2021 guidelines recommend that during the dying phase when death is expected within days, nutritional and metabolic support is usually not indicated. Artificial nutrition and hydration at end of life does not significantly improve survival or quality of life in terminal cancer patients. The focus should shift to comfort, dignity, and small amounts of preferred foods for sensory pleasure. Palliative care teams should proactively discuss nutrition expectations with families.

Does diet affect immunotherapy response in mesothelioma?

Emerging evidence suggests dietary patterns may significantly influence immunotherapy outcomes. The PRIMM study found that Mediterranean diet adherence was associated with a probability of ORR 0.77 (p=0.02) in patients receiving immune checkpoint inhibitors, and a 2025 systematic review reported that high fiber intake was associated with an OR of 5.79 for improved ICI response. Since nivolumab plus ipilimumab is first-line standard therapy for mesothelioma, these dietary-immunotherapy findings have direct clinical relevance, though mesothelioma-specific microbiome data is not yet available.

Quick Statistics

• 38% of MPM patients meet malnutrition criteria at diagnosis
• 54% are pre-sarcopenic at baseline
• 87% report appetite loss; 94% report fatigue
• PNI <44.6 carries HR 2.29 for death (p=0.001)
• Hypoalbuminemia associated with 44.1% vs 72.0% 1-year survival
• mGPS independently predicts survival with HR 2.6 (p<0.001)
• 25-30 kcal/kg/day recommended energy intake (ESPEN 2021)
• 1.0-1.5 g/kg/day recommended protein intake for cancer patients
• B12/folate supplementation adds 5 months median OS with pemetrexed
• Mediterranean diet associated with ORR probability 0.77 (p=0.02) with immunotherapy
• High fiber intake OR 5.79 for improved ICI response
• 29.3% of CRS/HIPEC patients require post-operative parenteral nutrition
• 75% of mesothelioma caregivers report personal health impacts
• Glutamine reduces severe mucositis (RR 0.41) and hospitalization (RR 0.39)

Get Help

• Danziger & De Llano -- Free consultation for mesothelioma patients and families. Call (866) 222-9990.
• Mesothelioma Lawyers Near Me -- Comprehensive resources on mesothelioma treatment, legal options, and patient support.
• Mesothelioma.net -- Treatment information and patient resources.

Related Pages

• Understanding Your Mesothelioma Diagnosis
• Mesothelioma Clinical Trials
• Mesothelioma Treatment Centers
• Mesothelioma Survival Statistics
• Mesothelioma Quick Facts